<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="14169"><DrugName>emepepimut-S</DrugName><DrugNamesKey><Name id="42999876">Stimuvax</Name><Name id="42999880">emepepimut-S</Name><Name id="42999365">tecemotide</Name></DrugNamesKey><DrugSynonyms><Name><Value>encapsulated MUC-1 peptide vaccine (cancer), Biomira</Value></Name><Name><Value>encapsulated MUC-1 peptide vaccine (cancer), Oncothyreon</Value></Name><Name><Value>tecemotide</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>L-BLP-25</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BLP-25 liposome vaccine</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>EMD 531444</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Stimuvax</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>emepepimut-S</Value><Types><Type>USAN</Type></Types></Name><Name><Value>ONO-7165</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BLP-25</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BP-24</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>221214-84-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14774">Cascadian Therapeutics Inc</CompanyOriginator><CompaniesSecondary><Company id="1035512">EMD Serono Inc</Company><Company id="14774">Cascadian Therapeutics Inc</Company><Company id="18101">Merck KGaA</Company><Company id="18681">Ono Pharmaceutical Co Ltd</Company><Company id="19862">Merck Serono SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="14169" type="Drug"><TargetEntity id="243623" type="siDrug">Tecemotide</TargetEntity></SourceEntity><SourceEntity id="1035512" type="Company"><TargetEntity id="5001188578" type="organizationId">EMD Serono Inc</TargetEntity></SourceEntity><SourceEntity id="14774" type="Company"><TargetEntity id="4295860458" type="organizationId">Cascadian Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="18101" type="Company"><TargetEntity id="4295869098" type="organizationId">Merck KGaA</TargetEntity></SourceEntity><SourceEntity id="18681" type="Company"><TargetEntity id="4295877874" type="organizationId">Ono Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="19862" type="Company"><TargetEntity id="4295890498" type="organizationId">Merck Serono SA</TargetEntity></SourceEntity><SourceEntity id="1055" type="ciIndication"><TargetEntity id="C20" type="ICD10"></TargetEntity><TargetEntity id="154.1" type="ICD9"></TargetEntity><TargetEntity id="10038038" type="MEDDRA"></TargetEntity><TargetEntity id="D012004" type="MeSH"></TargetEntity><TargetEntity id="-796050081" type="omicsDisease"></TargetEntity><TargetEntity id="640" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"></TargetEntity><TargetEntity id="D002289" type="MeSH"></TargetEntity><TargetEntity id="-1730468577" type="omicsDisease"></TargetEntity><TargetEntity id="612" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"></TargetEntity><TargetEntity id="10028228" type="MEDDRA"></TargetEntity><TargetEntity id="D009101" type="MeSH"></TargetEntity><TargetEntity id="29073" type="ORPHANET"></TargetEntity><TargetEntity id="-18870694" type="omicsDisease"></TargetEntity><TargetEntity id="710" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"></TargetEntity><TargetEntity id="10060862" type="MEDDRA"></TargetEntity><TargetEntity id="D011471" type="MeSH"></TargetEntity><TargetEntity id="-405461207" type="omicsDisease"></TargetEntity><TargetEntity id="637" type="siCondition"></TargetEntity><TargetEntity id="5083" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"></TargetEntity><TargetEntity id="10033128" type="MEDDRA"></TargetEntity><TargetEntity id="D010051" type="MeSH"></TargetEntity><TargetEntity id="-1370909262" type="omicsDisease"></TargetEntity><TargetEntity id="626" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="32078" type="Action"><TargetEntity id="5011" type="Mechanism">Mucin-1 (MUC-1) Inhibitors</TargetEntity><TargetEntity id="1588" type="Mechanism">Anti-CD227 (MUC1)</TargetEntity></SourceEntity><SourceEntity id="PTGT-06235" type="ciTarget"><TargetEntity id="181402999545823" type="siTarget">Mucin-1</TargetEntity><TargetEntity id="-1654932761" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1055">Rectal tumor</Indication><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="1828">Multiple myeloma</Indication><Indication id="276">Prostate tumor</Indication><Indication id="49">Breast tumor</Indication><Indication id="651">Cancer</Indication><Indication id="799">Ovary tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="32078">Mucin 1 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="12372">Protein subunit vaccine</Action><Action id="12379">Therapeutic vaccine</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="142">Liposome formulation</Technology><Technology id="1653">Tumor antigen</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology></Technologies><LastModificationDate>2019-06-27T12:36:23.000Z</LastModificationDate><ChangeDateLast>2019-07-01T00:00:00.000Z</ChangeDateLast><AddedDate>1996-12-11T14:52:57.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19862" linkType="Company"&gt;Merck Serono&lt;/ulink&gt; (a subsidiary of &lt;ulink linkID="18101" linkType="Company"&gt;Merck KGaA&lt;/ulink&gt;) and Japanese licensee &lt;ulink linkID="18681" linkType="Company"&gt;Ono Pharmaceutical&lt;/ulink&gt;, under license from &lt;ulink linkID="14774" linkType="Company"&gt;Oncothyreon&lt;/ulink&gt; (formerly Biomira),  were developing emepepimut-S (L-BLP-25; tecemotide; EMD-531444; ONO-7165; formerly known as Stimuvax), a liposome-encapsulated vaccine containing the MUC-1 peptide  tecemotide (BLP-25; BP-24), for the potential  treatment of cancer, including non-small-cell lung cancer (NSCLC).   In 2014, following negative data from the NSCLC program, Merck decided to discontinue development of the drug [&lt;ulink linkID="1642668" linkType="Reference"&gt;1642668&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;In December 2006, enrollment in a phase III trial (START) was initiated in unresectable stage III NSCLC patients who had a response to radiochemotherapy [&lt;ulink linkID="754578" linkType="Reference"&gt;754578&lt;/ulink&gt;], and a phase III trial (INSPIRE) in Asian patients with NSCLC following chemoradiotherapy began in December 2009 [&lt;ulink linkID="1063330" linkType="Reference"&gt;1063330&lt;/ulink&gt;]. However, in March 2010, all clinical development was temporarily suspended following a suspected serious adverse event in a phase II multiple myeloma (MM) trial. At that time, the FDA also placed a clinical hold on the IND application [&lt;ulink linkID="1084818" linkType="Reference"&gt;1084818&lt;/ulink&gt;], [&lt;ulink linkID="1084904" linkType="Reference"&gt;1084904&lt;/ulink&gt;]. In June 2010, Merck resumed the clinical program for NSCLC after the FDA partially lifted the hold on the START and INSPIRE NSCLC trials [&lt;ulink linkID="1108785" linkType="Reference"&gt;1108785&lt;/ulink&gt;], [&lt;ulink linkID="1108788" linkType="Reference"&gt;1108788&lt;/ulink&gt;]. In December 2012, it was reported that START did not meet its primary endpoint [&lt;ulink linkID="1351488" linkType="Reference"&gt;1351488&lt;/ulink&gt;]; at that time, Merck reported that it would not file for approval until at least 2014 [&lt;ulink linkID="1352945" linkType="Reference"&gt;1352945&lt;/ulink&gt;]. By September 2013, Merck had reviewed the START data, and decided to continue development in NSCLC as the data showed that patients with a treatment history of simultaneous chemotherapy and radiotherapy  responded better than patients who had received chemotherapy or radiation separately. The company would begin a new phase III trial (START2) in this setting [&lt;ulink linkID="1480733" linkType="Reference"&gt;1480733&lt;/ulink&gt;]; in March 2014, the START2 study was initiated  [&lt;ulink linkID="1539888" linkType="Reference"&gt;1539888&lt;/ulink&gt;]. In November 2013, the INSPIRE study was ongoing [&lt;ulink linkID="1503551" linkType="Reference"&gt;1503551&lt;/ulink&gt;]. By October 2011, the product was in phase II development in Japan for NSCLC [&lt;ulink linkID="1227790" linkType="Reference"&gt;1227790&lt;/ulink&gt;], [&lt;ulink linkID="1235535" linkType="Reference"&gt;1235535&lt;/ulink&gt;], however in August 2014, Merck recommended that no Japanese patients be enrolled into the phase III program following lack of efficacy seen in this trial [&lt;ulink linkID="1586277" linkType="Reference"&gt;1586277&lt;/ulink&gt;]. In September 2014, Merck discontinued the clinical development program for NSCLC following a review of the data from the Japanese EMR63325-009 study, stating that it was unlikely that the current trials for NSCLC would reach their goals [&lt;ulink linkID="1593483" linkType="Reference"&gt;1593483&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Development in other cancer indications was also previously undertaken. In June 2009, the vaccine entered  a phase III trial (STRIDE) in breast cancer [&lt;ulink linkID="1019991" linkType="Reference"&gt;1019991&lt;/ulink&gt;]; the trial remained on hold following the lifting of the NSCLC trial clinical hold in March 2010  [&lt;ulink linkID="1108785" linkType="Reference"&gt;1108785&lt;/ulink&gt;], [&lt;ulink linkID="1108788" linkType="Reference"&gt;1108788&lt;/ulink&gt;], and in July 2010, Merck Serono decided to close the STRIDE trial [&lt;ulink linkID="1121843" linkType="Reference"&gt;1121843&lt;/ulink&gt;]. In August 2002, Merck's pipeline also listed emepepimut-S in clinical development for ovarian cancer [&lt;ulink linkID="462282" linkType="reference"&gt;462282&lt;/ulink&gt;]; however, by October 2003, the drug  was no longer listed as under development for this indication [&lt;ulink linkID="508477" linkType="reference"&gt;508477&lt;/ulink&gt;]. In February 2008, a phase II study began in MM; the trial completed in early 2012 [&lt;ulink linkID="1107933" linkType="Reference"&gt;1107933&lt;/ulink&gt;], and following one fatal event in the trial it is presumed the indication is no longer under development [&lt;ulink linkID="1243859" linkType="Reference"&gt;1243859&lt;/ulink&gt;]. By October 2001, emepepimut-S was in phase II trials for prostate cancer [&lt;ulink linkID="426319" linkType="reference"&gt;426319&lt;/ulink&gt;]. Development for that indication was discontinued in August 2003 due to a lack of efficacy [&lt;ulink linkID="500140" linkType="reference"&gt;500140&lt;/ulink&gt;],   but, in November 2011, a phase II combination trial for prostate cancer began [&lt;ulink linkID="1252817" linkType="Reference"&gt;1252817&lt;/ulink&gt;]. In January 2012, a phase II trial (SPRINT) in rectal cancer was initiated. In June 2014, the trial was completed  [&lt;ulink linkID="1255553" linkType="Reference"&gt;1255553&lt;/ulink&gt;]. By December 2014, Merck had discontinued the development of the drug based on negative data from the NSCLC program  [&lt;ulink linkID="1642668" linkType="Reference"&gt;1642668&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Oncothyreon was also investigating a glycoprotein MUC-1 vaccine &lt;ulink linkID="45639" linkType="Drug"&gt;BGLP-40&lt;/ulink&gt; for the potential treatment of cancer [&lt;ulink linkID="755021" linkType="Reference"&gt;755021&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;Composition of matter patents for emepepimut-S expire in 2018.&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;In September 2004, the FDA granted emepepimut-S Fast Track status [&lt;ulink linkID="561597" linkType="Reference"&gt;561597&lt;/ulink&gt;].  By April 2008 (prior to the clinical hold), Merck planned to file the drug for US approval for NSCLC in 2011[&lt;ulink linkID="932247" linkType="Reference"&gt;932247&lt;/ulink&gt;]. In March 2010, the FDA placed  a clinical hold on the IND application following a suspected serious adverse reaction [&lt;ulink linkID="1084818" linkType="Reference"&gt;1084818&lt;/ulink&gt;], [&lt;ulink linkID="1084904" linkType="Reference"&gt;1084904&lt;/ulink&gt;]. In June 2010, Merck resumed the clinical program for NSCLC after the FDA partially lifted the clinical hold on the IND for the START and INSPIRE trials [&lt;ulink linkID="1108785" linkType="Reference"&gt;1108785&lt;/ulink&gt;], [&lt;ulink linkID="1108788" linkType="Reference"&gt;1108788&lt;/ulink&gt;]. However, in September 2014, Merck discontinued the clinical development program for NSCLC [&lt;ulink linkID="1593483" linkType="Reference"&gt;1593483&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;By April 2008 (prior to the clinical hold), Merck had planned to file the drug for EU approval for NSCLC in 2011[&lt;ulink linkID="932247" linkType="Reference"&gt;932247&lt;/ulink&gt;]. However, in September 2014, Merck discontinued the clinical development program for NSCLC [&lt;ulink linkID="1593483" linkType="Reference"&gt;1593483&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In September 2014, Merck discontinued the clinical development program for NSCLC [&lt;ulink linkID="1593483" linkType="Reference"&gt;1593483&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, Merck planned to begin START2 (&lt;ulink linkID="155853" linkType="Protocol"&gt;NCT02049151&lt;/ulink&gt;; EMR 63325-021, 2013-003760-30), a phase III trial in NSCLC patients that had been previously been treated with chemotherapy and radiotherapy simultaneously. The trial was to enroll 1000 patients in the US and Germany [&lt;ulink linkID="1480733" linkType="Reference"&gt;1480733&lt;/ulink&gt;], [&lt;ulink linkID="1539888" linkType="Reference"&gt;1539888&lt;/ulink&gt;].  By December 2013, the FDA had agreed an SPA for the multicenter, randomized, double-blind, placebo-controlled  trial for unresectable, locally advanced (Stage IIIA or IIIB) NSCLC. The primary endpoint was overall survival [&lt;ulink linkID="1507377" linkType="Reference"&gt;1507377&lt;/ulink&gt;]. By March 2014, the trial had started recruiting; at that time 1002 patients were expected to be enrolled and completion of the study was expected in July 2018 [&lt;ulink linkID="1539888" linkType="Reference"&gt;1539888&lt;/ulink&gt;]; in April 2014, the first patient was dosed [&lt;ulink linkID="1543446" linkType="Reference"&gt;1543446&lt;/ulink&gt;], [&lt;ulink linkID="1543508" linkType="Reference"&gt;1543508&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2009, the phase III double-blind, placebo-controlled, randomized INSPIRE trial (&lt;ulink linkID="62045" linkType="Protocol"&gt;NCT01015443&lt;/ulink&gt;) began in China, Hong Kong, South Korea, Singapore and Taiwan for unresectable stage III NSCLC Asian patients (n = 420) who had shown stable disease or objective response following primary chemoradiotherapy. The trial would assess progression-free survival, quality-of-life and safety. At that time, enrollment was open in Hong Kong and was subsequently to expand to the other territories [&lt;ulink linkID="1063330" linkType="Reference"&gt;1063330&lt;/ulink&gt;], [&lt;ulink linkID="1063310" linkType="Reference"&gt;1063310&lt;/ulink&gt;]. In June 2010, Merck resumed the clinical program for NSCLC after the FDA partially lifted the clinical hold on the IND for the START and INSPIRE trials; the study protocol for the trial was being amended to add specific safety measures; the trial was expected to complete in January 2018 [&lt;ulink linkID="1108785" linkType="Reference"&gt;1108785&lt;/ulink&gt;], [&lt;ulink linkID="1108788" linkType="Reference"&gt;1108788&lt;/ulink&gt;]. In September 2012, similar clinical design information was presented at the 1st SMI Cancer Vaccines meeting in London, UK [&lt;ulink linkID="1325432" linkType="Reference"&gt;1325432&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2005, the start of phase III trials was delayed due to a stability problem with the vaccine.  The delay allowed  Biomira and Merck KGaA to address a stability issue discovered during the manufacturing process [&lt;ulink linkID="624758" linkType="Reference"&gt;624758&lt;/ulink&gt;]. In December 2006, the FDA  agreed an SPA for the first phase III study.  The international, multicenter, randomized, double-blind, placebo-controlled trial would assess the vaccine in 1300 patients with unresectable stage IIIA and IIIB locoregional NSCLC. Overall survival was the primary endpoint [&lt;ulink linkID="750721" linkType="Reference"&gt;750721&lt;/ulink&gt;]. Later that month, the phase III START trial (&lt;ulink linkID="40316" linkType="Protocol"&gt;NCT00409188&lt;/ulink&gt;; EMR 63325-001) was initiated in stage III patients following chemoradiotherapy. Secondary outcomes would include time-to-symptom progression and time-to-progression. At that time, the trial was expected to  complete by December 2008 [&lt;ulink linkID="754578" linkType="Reference"&gt;754578&lt;/ulink&gt;], [&lt;ulink linkID="1085081" linkType="Reference"&gt;1085081&lt;/ulink&gt;]; however, in November 2009, enrollment was still ongoing [&lt;ulink linkID="1056388" linkType="Reference"&gt;1056388&lt;/ulink&gt;].  In June 2010, Merck resumed the clinical program for NSCLC after the FDA partially lifted the clinical hold on the IND for the START and INSPIRE trials; the study protocols for both trials were being amended to add specific safety measures [&lt;ulink linkID="1108785" linkType="Reference"&gt;1108785&lt;/ulink&gt;], [&lt;ulink linkID="1108788" linkType="Reference"&gt;1108788&lt;/ulink&gt;]. Furthermore, patients who were early in the treatment course at the time of the clinical hold may have been inadequately immunized to MUC1, thus Merck Serono planned to replace patients in the trial who had received less than 6 months of therapy at the time of the clinical hold, resulting in an increase in the size of the START trial from an estimated 1320 to 1476 patients. In late 2010, the Data Monitoring Committee for the START trial conducted its first interim review and determined that the trial should continue; the trial was expected to complete in  September 2014 [&lt;ulink linkID="1229742" linkType="Reference"&gt;1229742&lt;/ulink&gt;]. By March 2012, enrollment in START was complete; a further interim review had determined that the trial should continue to final analysis, and final results were expected in 2013 [&lt;ulink linkID="1268920" linkType="Reference"&gt;1268920&lt;/ulink&gt;], [&lt;ulink linkID="1268927" linkType="Reference"&gt;1268927&lt;/ulink&gt;]. In September 2012,   clinical trial design information was presented at the 1st SMI Cancer Vaccines meeting in London, UK. At that time,     1514 patients have been recruited to the START trial and were randomized 2:1 to receive treatment or placebo.  For the study, 705 overall survival events were being sought  as a primary endpoint [&lt;ulink linkID="1325432" linkType="Reference"&gt;1325432&lt;/ulink&gt;], [&lt;ulink linkID="1325564" linkType="Reference"&gt;1325564&lt;/ulink&gt;].  In December 2012, it was reported that the trial failed to meet the primary endpoint; however, treatment effects were observed in certain, undisclosed subgroups  [&lt;ulink linkID="1351488" linkType="Reference"&gt;1351488&lt;/ulink&gt;]. In June 2013,  data were presented at the 49th ASCO meeting in Chicago, IL. The median overall survival (primary endpoint) duration in emepepimut-S-treated patients (n = 829) was 25.6 months when compared with 22.3 months in placebo-treated (n = 410) patients. Emepepimut-S treatment was well tolerated [&lt;ulink linkID="1426856" linkType="Reference"&gt;1426856&lt;/ulink&gt;], [&lt;ulink linkID="1422018" linkType="Reference"&gt;1422018&lt;/ulink&gt;]. Further data  presented at ASCO showed that, following a post-hoc analysis in a predefined subgroup of patients receiving initial concurrent chemoradiotherapy, an overall survival of 30.8 months was observed in patients treated with emepepimut-S, compared to 20.6 months in patients receiving placebo  [&lt;ulink linkID="1461669" linkType="Reference"&gt;1461669&lt;/ulink&gt;], [&lt;ulink linkID="1480733" linkType="Reference"&gt;1480733&lt;/ulink&gt;]. In September 2013, data from 1239 patients were presented at the 2013 European Cancer Congress in Amsterdam, the Netherlands. The median overall survival was 26.2 months with tecemotide compared with 22.4 months for placebo (primary endpoint). Tecemotide prolonged time to symptom progression and time to progression compared with placebo. This effect of tecemotide was more pronounced in the concurrent chemoradiotherapy subgroup than in the sequential chemoradiotherapy subgroup [&lt;ulink linkID="1480267" linkType="Reference"&gt;1480267&lt;/ulink&gt;]. In October 2013, further data were presented from the double-blind study at the 15th World Conference on Lung Cancer in Sydney, Australia. In both the treatment groups, difference in health status was not observed. Regardless the treatment type, an association was observed between the disease progression and health status deterioration [&lt;ulink linkID="1491519" linkType="Reference"&gt;1491519&lt;/ulink&gt;]. In December 2013, similar data were published [&lt;ulink linkID="1507377" linkType="Reference"&gt;1507377&lt;/ulink&gt;], [&lt;ulink linkID="1507609" linkType="Reference"&gt;1507609&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;By October 2010, the phase II EMR63325-009 trial was underway in Japan in patients with NSCLC [&lt;ulink linkID="1227790" linkType="Reference"&gt;1227790&lt;/ulink&gt;]. By August 2014, Merck had reported that the 178-patient trial did not meet its primary endpoint of improved overall survival, and no treatment effect was seen in any of the secondary endpoints (PFS, TTP, TTTF). Merck recommended that no recruitment of Japanese patients into the phase III program take place [&lt;ulink linkID="1586277" linkType="Reference"&gt;1586277&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, a Canadian phase II single-arm, multicenter, open-label study of the vaccine formulation to be used in the phase III trial had been initiated  in  20  patients with  NSCLC [&lt;ulink linkID="596318" linkType="Reference"&gt;596318&lt;/ulink&gt;], [&lt;ulink linkID="601270" linkType="Reference"&gt;601270&lt;/ulink&gt;]. In September 2005, Biomira completed enrollment in the phase II safety trial [&lt;ulink linkID="622689" linkType="Reference"&gt;622689&lt;/ulink&gt;].  In June 2007, data were presented at the 43rd ASCO meeting in Chicago, IL. A total of 16 patients were evaluable for the interim safety results; 13  had a partial response and 3 had stable disease. A total of 13 patients experienced an adverse event, although no serious toxicities were reported. As of October 2006, ten individuals were still on trial. Based on the data, the tecemotide formulation was determined not to differ from the previous formulation in terms of safety [&lt;ulink linkID="797198" linkType="Reference"&gt;797198&lt;/ulink&gt;]. In June 2008, further results were presented at the 44th annual ASCO meeting in Chicago, IL. All 22 patients were evaluable; 1 patient had a complete response, 17 had partial responses and 4 had stable disease. After a median follow up of 26.7 months, the 2-year overall survival rate was 64% [&lt;ulink linkID="912536" linkType="Reference"&gt;912536&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2000, Biomira initiated a multicenter, controlled phase IIb trial of emepepimut-S in stage IIIB and IV NSCLC, which was expected to enroll 166 patients in the UK and Canada. Patients were to be randomized to emepepimut-S plus best supportive care or to best supportive care alone [&lt;ulink linkID="407728" linkType="reference"&gt;407728&lt;/ulink&gt;], [&lt;ulink linkID="378515" linkType="reference"&gt;378515&lt;/ulink&gt;], [&lt;ulink linkID="399613" linkType="reference"&gt;399613&lt;/ulink&gt;], [&lt;ulink linkID="458789" linkType="reference"&gt;458789&lt;/ulink&gt;]. By January 2002, an independent Data Safety Monitoring Board (DSMB) had reviewed safety data from the first 50 patients enrolled the trial [&lt;ulink linkID="437944" linkType="reference"&gt;437944&lt;/ulink&gt;]; the report revealed no safety concerns preventing the trial from continuing [&lt;ulink linkID="452191" linkType="reference"&gt;452191&lt;/ulink&gt;]. In July 2002, an independent DSMB had reviewed safety data from the first 100 patients enrolled in the trial and recommended that the study continue as planned [&lt;ulink linkID="458789" linkType="reference"&gt;458789&lt;/ulink&gt;]. In November 2002, Biomira completed enrollment of the planned 166 patients. Recruitment in the trial was extended to allow a few previously identified patients the opportunity to be included [&lt;ulink linkID="470010" linkType="reference"&gt;470010&lt;/ulink&gt;]. Final enrollment had been completed by February 2003, at 171 patients [&lt;ulink linkID="480212" linkType="reference"&gt;480212&lt;/ulink&gt;], [&lt;ulink linkID="511331" linkType="reference"&gt;511331&lt;/ulink&gt;]. In April 2004, preliminary results were reported, showing that median survival time in the treatment arm was 17.4 months, compared to 13 months in the control arm; however, this difference was not  significant. The 2-year survival rate for patients with locoregional stage IIIb disease was 60% for the vaccine arm (median survival not reached), compared to 36.7% for the control arm (median survival of 13.3 months). In the overall patient population, the 2-year survival was 43.2% for the vaccine arm, compared to 28.9% for the control arm. Emepepimut-S had a favorable safety profile [&lt;ulink linkID="530445" linkType="reference"&gt;530445&lt;/ulink&gt;]. By September 2004,  results from this trial had been presented to the FDA [&lt;ulink linkID="561597" linkType="Reference"&gt;561597&lt;/ulink&gt;]. Similar data were presented in November 2004 at the 29th Meeting of the European Society for Medical Oncology in Vienna, Austria [&lt;ulink linkID="567900" linkType="Reference"&gt;567900&lt;/ulink&gt;]. In December 2004, data from a subset of patients were published showing that 23 months after completion of enrollment in the trial, no median survival time had been reached in patients with stage IIIB locoregional NSCLC [&lt;ulink linkID="574493" linkType="Reference"&gt;574493&lt;/ulink&gt;], [&lt;ulink linkID="574520" linkType="Reference"&gt;574520&lt;/ulink&gt;]. Similar data were presented in May 2005 at the 41st ASCO meeting in Orlando, FL [&lt;ulink linkID="603445" linkType="Reference"&gt;603445&lt;/ulink&gt;], [&lt;ulink linkID="601492" linkType="Reference"&gt;601492&lt;/ulink&gt;]. By October 2005, a median survival time of 30.6 months for  stage IIB locoregional NSCLC patients in the vaccine arm had been reported, compared with 13.3 months in the control arm [&lt;ulink linkID="630746" linkType="Reference"&gt;630746&lt;/ulink&gt;]. In April 2006, similar final data were reported [&lt;ulink linkID="664542" linkType="Reference"&gt;664542&lt;/ulink&gt;]; similar data were also presented in November 2006, at the 11th Perspectives on Thoracic Oncology meeting in New York, NY [&lt;ulink linkID="747711" linkType="Reference"&gt;747711&lt;/ulink&gt;]. In September 2007, further data were presented at the International Association for the Study of Lung Cancer (IASLC) Congress in Seoul, South Korea; 3-year survival data was 49% for vaccine-treated patients, compared to 27% for best supportive care, representing a  45% reduction in mortality [&lt;ulink linkID="827784" linkType="Reference"&gt;827784&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2009, data were presented at the 45th ASCO meeting in Orlando, FL. Patients (n = 171) received emepepimut-S sc at a dose of 1000 microg qw, in combination with cyclophosphamide. The drug was well tolerated with no evidence of autoimmune reactions, renal, liver or other life-threatening adverse effects with prolonged use [&lt;ulink linkID="1008997" linkType="Reference"&gt;1008997&lt;/ulink&gt;], [&lt;ulink linkID="1014093" linkType="Reference"&gt;1014093&lt;/ulink&gt;], [&lt;ulink linkID="1014265" linkType="Reference"&gt;1014265&lt;/ulink&gt;]. In August 2009, data related to long-term treatment with emepepimut-S were presented at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer in San Francisco, CA. Of 16 patients treated for between 2 and 8.2 years, 10 were alive without any disease progression, of which 8 had received the drug for 6.3 to 8.2 years, and 2 discontinued the  therapy after 2.4 and 5.8 years. Out of 10 living patients, 6 showed a complete response to their first-line chemotherapy, while  4 had stable disease. The remaining 6 of the 16 patients discontinued the drug after 2.0 to 5.1 years of treatment as a result of disease progression and were deceased. The vaccine was well tolerated [&lt;ulink linkID="1030594" linkType="Reference"&gt;1030594&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2008, the company began a German phase I/II trial in patients with stage III unresectable NSCLC (&lt;ulink linkID="59635" linkType="Protocol"&gt;NCT00960115&lt;/ulink&gt;; EMR063325_009). The trial would enroll 168 patients and the primary endpoint would be overall survival time. The trial was expected to complete in December 2014 [&lt;ulink linkID="1035080" linkType="Reference"&gt;1035080&lt;/ulink&gt;]. In May 2015, data were presented at the 51st ASCO meeting in Chicago, IL. In the intent-to-treat population, no trend towards improved median overall survival was observed with tecemotide compared with placebo. Similar progression-free survival, time to progression and time to failure were observed with tecemotide and placebo [&lt;ulink linkID="1662206" linkType="Reference"&gt;1662206&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2000, data on emepepimut-S were presented at the EXPO 2000 World Exhibition in Hannover, Germany. Phase I/II study data were highlighted showing that  in NSCLC patients, the vaccine was well tolerated and capable of generating a powerful and strong cellular immune response against MUC-1 antigen [&lt;ulink linkID="385989" linkType="reference"&gt;385989&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 1999, Biomira initiated a phase II Canadian trial of emepepimut-S in patients with advanced NSCLC to determine if higher or more frequent dosing would enhance its effects [&lt;ulink linkID="335997" linkType="reference"&gt;335997&lt;/ulink&gt;]. Patient enrollment was completed in December 1999. The trial involved seven patients, although the company intended to continue accepting patients into the trial until the second stage of testing began, in which emepepimut-S was to be administered to up to 20 patients in combination with liposomal IL-2 (LIL-2)  [&lt;ulink linkID="351199" linkType="reference"&gt;351199&lt;/ulink&gt;]. Results indicated strong MUC-1 specific T-cell proliferation in six out of eight evaluable patients with NSCLC [&lt;ulink linkID="360962" linkType="reference"&gt;360962&lt;/ulink&gt;]. By February 2001, half the patients were still alive [&lt;ulink linkID="399613" linkType="reference"&gt;399613&lt;/ulink&gt;]. The second phase of a parallel phase II trial was initiated in January 2000, in which patients with advanced NSCLC received emepepimut-S in combination with LIL-2. The purpose of the study was to determine if the effect of emepepimut-S was enhanced by LIL-2, while preserving a satisfactory safety profile [&lt;ulink linkID="353448" linkType="reference"&gt;353448&lt;/ulink&gt;]. By February 2001, the trial had completed enrollment of 18 patients [&lt;ulink linkID="399613" linkType="reference"&gt;399613&lt;/ulink&gt;]. The first 10 patients enrolled received 500,000 IU of L-IL-2 per weekly injection and the next eight patients received 2 million IU of L-IL-2. Both doses of L-IL-2 used in combination with BLP25 vaccine showed acceptable safety and tolerability profiles. However, there was no apparent improvement in immune response parameters over BLP25 vaccine alone [&lt;ulink linkID="422889" linkType="Reference"&gt;422889&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In September 2001, Biomira published results from a phase I study of emepepimut-S which involved 16 evaluable patients with NSCLC. Patients were randomized into two groups receiving 20 and 200 mg doses of the vaccine. Both doses were well tolerated. Immunological assays revealed the generation of cytotoxic T-lymphocytes (CTLs) against MUC-1 positive tumor cell lines in 5 of 12 patients. These patients did not have MUC-1 specific CTLs prior to receiving the vaccine [&lt;ulink linkID="422889" linkType="reference"&gt;422889&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 1998, a phase I safety and dose comparison trial began in patients with NSCLC (n = 14) [&lt;ulink linkID="293436" linkType="reference"&gt;293436&lt;/ulink&gt;], [&lt;ulink linkID="313395" linkType="reference"&gt;313395&lt;/ulink&gt;]. The trial was completed in March 1999. Results showed that emepepimut-S was safe and triggered a cytotoxic T-cell response. Following a preliminary analysis of the results, an independent panel recommended the trial continue [&lt;ulink linkID="319960" linkType="reference"&gt;319960&lt;/ulink&gt;], [&lt;ulink linkID="339620" linkType="reference"&gt;339620&lt;/ulink&gt;]. In May 2000, data were presented at the 36th ASCO meeting in New Orleans, LA. In 5 out of 12 evaluable patients with stage IIIb and stage IV NSCLC, the vaccine elicited a cytotoxic T-lymphocyte response and was well tolerated. Final survival data on patients treated with either a 20 or 200 mg dose of emepepimut-S were also presented; median survival time of patients treated with the 20 mg dose regimen was 5.5 months, compared to 14.7 months for 200 mg emepepimut-S [&lt;ulink linkID="368999" linkType="reference"&gt;368999&lt;/ulink&gt;], [&lt;ulink linkID="367786" linkType="reference"&gt;367786&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Breast cancer&lt;/subtitle&gt;In June 2009, a phase III trial for advanced, inoperable, hormone-sensitive breast cancer began. During the treatment phase of the first arm of the randomized, double-blind, controlled, multinational STRIDE study (&lt;ulink linkID="58156" linkType="Protocol"&gt;NCT00925548&lt;/ulink&gt;; EMR 200038-010), patients (n = 909) would receive 1000 microg of emepepimut-S weekly plus hormone therapy for 8 weeks, following pretreatment with 300 mg/m2 iv cyclophosphamide. After the treatment phase, patients would receive emepepimut-S plus hormone therapy every 6 weeks until disease progression. Patients in the second arm would receive placebo weekly plus hormone therapy for 8 weeks following pretreatment with placebo. After the treatment phase, patients would receive placebo plus hormone therapy every 6 weeks until disease progression. The primary outcome was progression-free survival. Overall survival, quality of life, tumor response and safety would also be evaluated. The study was expected to complete in September 2012 [&lt;ulink linkID="1020321" linkType="Reference"&gt;1020321&lt;/ulink&gt;], [&lt;ulink linkID="1020036" linkType="Reference"&gt;1020036&lt;/ulink&gt;], [&lt;ulink linkID="1019991" linkType="Reference"&gt;1019991&lt;/ulink&gt;]. In November 2009, patient enrollment was ongoing [&lt;ulink linkID="1056388" linkType="Reference"&gt;1056388&lt;/ulink&gt;]. However, in March 2010, all clinical development was temporarily suspended following a suspected unexpected serious adverse event in the phase II MM trial. At that time, the FDA also placed a clinical hold on the IND application [&lt;ulink linkID="1084818" linkType="Reference"&gt;1084818&lt;/ulink&gt;], [&lt;ulink linkID="1084904" linkType="Reference"&gt;1084904&lt;/ulink&gt;]. In June 2010,  the STRIDE trial was still on clinical hold [&lt;ulink linkID="1108785" linkType="Reference"&gt;1108785&lt;/ulink&gt;], [&lt;ulink linkID="1108788" linkType="Reference"&gt;1108788&lt;/ulink&gt;]. In July 2010, Merck Serono decided to close the trial [&lt;ulink linkID="1121843" linkType="Reference"&gt;1121843&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2000,  data from a phase I trial in patients with recurrent metastatic breast cancer treated with dendritic cells incubated with emepepimut-S  were presented at the 36th ASCO meeting in New Orleans, LA. At 1 month, one patient had stable disease after prior progression, two patients had continuing stable disease and three experienced further progression. No significant toxicity was observed and fatigue was the most frequently reported side effect [&lt;ulink linkID="367712" linkType="reference"&gt;367712&lt;/ulink&gt;], [&lt;ulink linkID="368641" linkType="reference"&gt;368641&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;In November 2011, a randomized, open-label, parallel-assignment, phase II trial (&lt;ulink linkID="83432" linkType="Protocol"&gt;NCT01496131&lt;/ulink&gt;; EMR 63325-015; BB-IND 7787) of L-BLP25 plus standard androgen deprivation therapy and radiation therapy began in newly diagnosed, high-risk prostate cancer patients (expected n = 48) in the US. The primary endpoint was change from baseline in the levels of mucin-1 specific T cells. At that time, the trial was expected to complete in September 2015. In November 2016, the trial had completed [&lt;ulink linkID="1252817" linkType="Reference"&gt;1252817&lt;/ulink&gt;]. In April 2017, clinical data from 28 patients were presented at the 108th AACR Annual Meeting in Washington DC. Compared with androgen deprivation therapy (ADT) alone, greater increase in diffusion (p = 0.031) was observed with ADT + tecemotide treatment [&lt;ulink linkID="1914369" linkType="Reference"&gt;1914369&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2004, phase II data were presented at the 40th ASCO meeting in New Orleans, LA. Patients with prostate cancer who had PSA failures post-prosatectomy received a single iv dose of cyclophosphamide (300 mg/m2) followed by 8 weekly sc  vaccinations with emepepimut-S containing 1000 microg of antigen. Subsequent vaccinations were given at 6 week intervals until week 49. From 15 evaluable patients, 8 had either stabilization or decrease in PSA. At the last-on-study PSA measurement, one patient maintained a stable PSA, but all others had progressed. However, 6 out of 15 patients had a &amp;gt; 50% prolongation of PSA doubling time compared to pre-study [&lt;ulink linkID="543540" linkType="reference"&gt;543540&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2001, the first phase II trial of emepepimut-S in prostate cancer was initiated. The primary endpoint was to reduce or stabilize PSA values in patients with rising PSA after radical prostatectomy. Immune response and safety were to be measured as secondary endpoints [&lt;ulink linkID="426319" linkType="reference"&gt;426319&lt;/ulink&gt;].  In August 2003, Biomira reported that results from this trial did not conclusively show an effect on rising PSA levels. At this time, the company terminated development of emepepimut-S for this indication [&lt;ulink linkID="500140" linkType="reference"&gt;500140&lt;/ulink&gt;]. However, in February 2004, Biomira reported that there appeared to be a prolongation of PSA doubling time in 40% of patients in the study [&lt;ulink linkID="524950" linkType="reference"&gt;524950&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ovarian cancer&lt;/subtitle&gt;As of August 2002, Merck's pipeline listed emepepimut-S as in development for ovarian cancer [&lt;ulink linkID="462282" linkType="reference"&gt;462282&lt;/ulink&gt;]. However, by October 2003, this indication was no longer listed [&lt;ulink linkID="508477" linkType="reference"&gt;508477&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rectal cancer&lt;/subtitle&gt;In January 2012, a randomized, parallel-group, open-label, phase II trial (&lt;ulink linkID="83873" linkType="Protocol"&gt;NCT01507103&lt;/ulink&gt;; EMR063325-013; 2011-000847-25; SPRINT) began in patients (expected n = 87) in the Netherlands with newly diagnosed rectal cancer who were eligible for neoadjuvant therapy. The primary endpoint was change from baseline of tumor-infiltrating lymphocytes and MUC1- and CEA-specific T cells at 4 months. At that time, the trial was expected to complete in June 2013. In June 2014, the trial was completed [&lt;ulink linkID="1255553" linkType="Reference"&gt;1255553&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Multiple myeloma&lt;/subtitle&gt;In February 2008, a phase II, randomized, open-label, parallel-assignment, safety/efficacy trial (&lt;ulink linkID="65487" linkType="Protocol"&gt;NCT01094548&lt;/ulink&gt;; EMR63325-008) began in Germany in patients (n = 45) with either chemotherapy-naive, slowly-progressive, asymptomatic MM, or stage II/III disease in stable response or plateau phase following antitumor therapy. The primary endpoint was anti-MUC-1 T-cell response. The study completed in March 2012 [&lt;ulink linkID="1107933" linkType="Reference"&gt;1107933&lt;/ulink&gt;]. In March 2010, one patient receiving emepepimut-S in combination with an intensified schedule of low-dose cyclophosphamide developed encephalitis, and a temporary clinical hold was placed on all clinical development  [&lt;ulink linkID="1084818" linkType="Reference"&gt;1084818&lt;/ulink&gt;], [&lt;ulink linkID="1084904" linkType="Reference"&gt;1084904&lt;/ulink&gt;]. In December 2011, data were presented at the 53rd ASH meeting in San Diego, CA. A total of 34 patients were treated with a single or multiple dose of cyclophosphamide followed by once-weekly emepepimut-S for 8 weeks and maintenance vaccination every 6 weeks until disease progression. Induction of MUC1 response was seen in 53% of patients following and a reduction in the slope of on-study M-protein concentration was seen over time in 13 subjects. There was one treatment-related fatal event of encephalitis [&lt;ulink linkID="1243859" linkType="Reference"&gt;1243859&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;OTHER STUDIES&lt;/subtitle&gt;In August 2011, a randomized, double-blind, parallel-assigned, interventional, phase II trial (&lt;ulink linkID="81976" linkType="Protocol"&gt;NCT01462513&lt;/ulink&gt;; LICC01) began in Austria and Germany in patients (n = 122) with Colon Carcinoma and rectum carcinoma. The trial completed in January 2018 [&lt;ulink linkID="1195526" linkType="Reference"&gt;1195526&lt;/ulink&gt;]. In June 2019, final data were presented at the 55th ASCO Annual Meeting in Chicago, IL. Median recurrence free survival (RFS; co-primary endpoint) was 6.1 versus 11.4 months for tecemotide versus placebo treatment group and estimated three-year overall survival (OS; co-primary endpoint) rate 69.1 versus 79.1%, respectively. Two-factorial Cox regression models exhibited no impact of MUC1 expression or treatment on RFS or OS (primary endpoint). Most commonly reported tecemotide -related grade 3/4 adverse events were diarrhea, anemia and back pain [&lt;ulink linkID="2155905" linkType="Reference"&gt;2155905&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2013, preclinical data were presented at the 104th AACR Meeting in Washington DC. Data demonstrated that at 24h after the 8th dose of emepepimut-S, Th 1 cytokine IL-12, IL-2 and IFN-gamma were induced by the prior administration of low dose cyclophosphamide to emepepimut-S when compared to  emepepimut-S alone  in hMUC1 transgenic mice. Data also demonstrated that Th2 cytokines and some inflammatory cytokines were increased  to a lesser extent [&lt;ulink linkID="1400048" linkType="Reference"&gt;1400048&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;n April 2013, preclinical data from studies in pancreatic cancer were presented at the 104th AACR Meeting in Washington DC. The combination of emepepimut-S (100 microg) and cyclophosphamide (100 mg/kg) significantly inhibited  the tumor growth in a sc model of Panc02/MUC1 murine pancreatic cancer in MUC1 transgenic mice and showed significant elevations in various splenic cell populations such as splenic CD8 effector memory/T-regulatory ratio, natural killer (NK) cells, neutrophils and splenic macrophages when compared with vehicle, cyclophosphamide or emepepimut-S alone. In TI09-077 study, in Panc02/MUC1 model, the combination significantly inhibited the tumor growth  with 56% of reduction when compared with the vehicle and sc administration showed 55% of inhibition of tumor growth when compared with the intradermal vaccination. Intradermal emepepimut-S as a single agent reduced the tumor volume (52% reduction). Sc administration of the combination showed a significant prolongation in survival with the median survival of 67 days when compared with the control (50.5 days) in TI10-037 study and showed a greater tumor volume when compared with the T-cell sufficient mice after T-cell depletion. The frequency of IFN-gamma producing CD4+ T cells isolated from mice spleen was significantly higher with the combination in an orthotopic model of pancreatic cancer. Elevations in the percentage of splenic NK cells, CD8+ and central memory T cells and improvement in median survival were observed with the combination alone in TI10-063 study [&lt;ulink linkID="1400938" linkType="Reference"&gt;1400938&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The peptide tecemotide was known as BP-24 in all preclinical studies. It became known as BLP-25 when it went into clinical trials [&lt;ulink linkID="457994" linkType="reference"&gt;457994&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2000, preclinical data were reported; dendritic cells were incubated with emepepimut-S prior to incubation with the donors'  T cells. The drug demonstrated  a strong primary T-cell response against  MUC-1 from 86% of normal donors [&lt;ulink linkID="360962" linkType="reference"&gt;360962&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 1998,  data were presented at the Fifth International IBC Conference on Vaccine Technologies in Washington, DC. In a metastatic lung cancer model  with human MUC-1  expressed on the cell surface, emepepimut-S prevented the appearance of lung metastases when given in advance of the cancer cells; untreated specimens developed an average of 39 metastases. In another model, emepepimut-S was injected after the cancer had established  microscopic cancer nodules; the  cancer cells  were completely eradicated following administration. The therapeutic effect of the emepepimut-S vaccine candidate was superior to &lt;ulink linkID="18119" linkType="Drug"&gt;BP-16&lt;/ulink&gt; [&lt;ulink linkID="278438" linkType="reference"&gt;278438&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 1998,  preclinical data were reported.  MUC-1 mucin secreted by cancer cells decreased the activity of certain immune response cells, including killer T cells, and inhibited the immune T-cell response by &amp;gt; 70%. The introduction of IL-2 reversed the T-cell suppression caused by MUC-1 mucin, and enhanced the cellular immune response over 100-fold [&lt;ulink linkID="274576" linkType="reference"&gt;274576&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Emepepimut-S incorporates a 25 amino acid sequence of a MUC1 cancer antigen in a liposomal formulation [&lt;ulink linkID="1229742" linkType="Reference"&gt;1229742&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, Ono and Merck Serono entered into a codevelopment and comarketing agreement for emepepimut-S in Japan [&lt;ulink linkID="1227790" linkType="Reference"&gt;1227790&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2011, the manufacture of emepepimut-S had been outsourced pursuant to agreements with &lt;ulink linkID="14437" linkType="Company"&gt;Baxter&lt;/ulink&gt; (for the manufacture of Stimuvax) and &lt;ulink linkID="15542" linkType="Company"&gt;Corixa&lt;/ulink&gt; (for the manufacture of the adjuvant used in Stimuvax) [&lt;ulink linkID="1229742" linkType="Reference"&gt;1229742&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2001,  Merck KGaA and originator &lt;ulink linkID="22646" linkType="Company"&gt;Biomira&lt;/ulink&gt; (now &lt;ulink linkID="14774" linkType="Company"&gt;Oncothyreon&lt;/ulink&gt;) entered a global product development and copromotion collaboration for emepepimut-S  [&lt;ulink linkID="408105" linkType="reference"&gt;408105&lt;/ulink&gt;]. In March 2006, Merck and Biomira amended the agreement, whereby Merck was to take over administrative and financial responsibility for development and commercialization of  the vaccine. All development, regulatory, commercialization and marketing costs excluding  Canada would be borne exclusively by Merck effective March 1, 2006. Biomira's copromtion interest in US sales would convert to a specified interest rate [&lt;ulink linkID="647109" linkType="Reference"&gt;647109&lt;/ulink&gt;]. By June 2010, it was presumed that &lt;ulink linkID="1035512" linkType="Company"&gt;EMD Serono&lt;/ulink&gt; (Merck KGaA's North American affliate) had acquired Canadian rights; Biomira retained manufacturing rights [&lt;ulink linkID="1108785" linkType="Reference"&gt;1108785&lt;/ulink&gt;]. In December 2008, the collaboration arrangement with Merck was replaced with a license agreement, pursuant to which Merck  gained sole responsibility for the clinical development, manufacture and commercialization of emepepimut-S [&lt;ulink linkID="1229742" linkType="Reference"&gt;1229742&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1991, Biomira acquired from &lt;ulink linkID="30620" linkType="Company"&gt;Cancer Research Technology Ltd&lt;/ulink&gt; (CTRL) an exclusive worldwide license of CRTL's rights to the Mucin 1 peptide antigen. This license agreement was amended and restated in November 2000, requiring Biomira to pay royalties in the mid single digits to CTRL until patent expiry in the US. In 2001, Biomira entered an exclusive license with the &lt;ulink linkID="20525" linkType="Company"&gt;University of Alberta&lt;/ulink&gt; for certain patents relating to uses of liposomal cancer vaccines of MUC1, and an adjuvant lipid A, for vaccine formulation use in emepepimut-S [&lt;ulink linkID="1229742" linkType="Reference"&gt;1229742&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Michael A Morse, &lt;ulink linkType="Company" linkID="20567"&gt;Duke University&lt;/ulink&gt; Medical Centre, Durham, NC, USA &lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;02 January 2001&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Cancer immunotherapy, the harnessing of immune effectors for the treatment of malignancies, is based on the observation that many tumors express antigens that may be recognized by immune effectors. One such antigen is the human mucin MUC-1. Mucins, high molecular weight glycoproteins, are found on the surface of many normal cells as well as pulmonary, breast and gastrointestinal cancers, and are involved in cell communication. In addition to altered patterns of glycosylation of tumor-associated mucin that may unveil targets for immune recognition, the mucin core protein contains repeated peptide structures that may be recognized by T-cells in an HLA non-restricted fashion. In order to capitalize on the immunogenicity of the core peptides, &lt;ulink linkType="Company" linkID="14774"&gt;Biomira Inc&lt;/ulink&gt; is developing a liposomal formulation of a 25-amino-acid MUC-1 peptide vaccine for the treatment of various cancers. Currently, &lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; is in phase II trials for non-small cell lung cancer (NSCLC) [&lt;ulink linkType="reference" linkID="335997"&gt;335997&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="353448"&gt;353448&lt;/ulink&gt;]. More recently, because many [&lt;ulink linkType="reference" linkID="395065"&gt;395065&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="395067"&gt;395067&lt;/ulink&gt;], but not all investigators [&lt;ulink linkType="reference" linkID="395070"&gt;395070&lt;/ulink&gt;] have observed that the MUC-1 mucin secreted by cancer cells inhibits T-cell responses and that this inhibition could partially be abrogated by the addition of IL-2 [&lt;ulink linkType="reference" linkID="349891"&gt;349891&lt;/ulink&gt;], the addition of IL-2 to the vaccine has been proposed [&lt;ulink linkType="reference" linkID="274576"&gt;274576&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="295758"&gt;295758&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; is 25-amino-acid peptide of sequence STAPPAHGVTSAPDTRPAPGSTAPP. The influence of liposome incorporation on immune response was investigated and it was found that encapsulated or surface-exposed peptide liposomes elicited strong antigen-specific T-cell responses [&lt;ulink linkType="reference" linkID="392736"&gt;392736&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;Various MUC-1 peptides of lengths varying from eight or nine amino acids to &amp;gt; 100 have been described. Guan and colleagues [&lt;ulink linkType="reference" linkID="392736"&gt;392736&lt;/ulink&gt;] studied &lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; and how its association with lipid affected immune responses. Lipid conjugated and non-conjugated human MUC-1 peptide &lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; were incorporated in liposomes with a composition of distearoylphosphatidylcholine/cholesterol/dimyristoylphosphatidylglycerol (3:1:0.25 molar ratio) containing monophosphoryl lipid A (1% w/w of the total lipids). C57BL/6 mice were immunized with lipopeptide alone, peptide mixed with peptide-free liposomes, and peptide associated with liposomes in entrapped or surface-exposed forms. Physically associated, either encapsulated or surface-exposed, peptide liposomes elicited strong antigen-specific Th1-cell responses, but lipopeptide alone or peptide mixed with peptide-free liposomes did not. Data from a preclinical study where dendritic cells were incubated with &lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt;, prior to incubation with the donors' T-cells, demonstrated that 86% of normal donors were able to generate a strong primary T-cell reponse against MUC-1 [&lt;ulink linkType="reference" linkID="360962"&gt;360962&lt;/ulink&gt;]. Agrawal [&lt;ulink linkType="reference" linkID="392749"&gt;392749&lt;/ulink&gt;] studied MUC-1 peptide-specific type 1 T-cell responses generated in vitro using human peripheral blood lymphocytes, incubated with liposomes containing synthetic MUC-1 lipopeptide. Potent anti-MUC-1-specific T-cell proliferation as well as class I-restricted cytotoxic responses were demonstrated after two weekly stimulations with the liposomal MUC-1 formulation. Scientists at &lt;ulink linkType="Company" linkID="14774"&gt;Biomira&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="284030"&gt;284030&lt;/ulink&gt;] tested a 24 mer (human MUC-1) synthetic peptide encapsulated with monophosphoryl lipid A adjuvant (MPLA) in multilamellar liposomes in a human MUC-1-transfected mouse mammary adenocarcinoma model. A low dose of the human MUC-1 peptide (5 microg) administered in liposomes protected mice from tumor challenge. MUC-1-specific T-cell proliferation, IFNgamma production and IgG2a anti-MUC-1 antibodies, consistent with a type 1 (T1) T-cell response were all observed. In a preclinical MUC-1 + metastatic lung cancer model, &lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; prevented the appearance of lung metastases when given prior to tumor challenge, and almost completely eradicated tumor when administered after the cancer had established small, microscopic cancer nodules [&lt;ulink linkType="reference" linkID="278438"&gt;278438&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;No specific data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No significant toxicity has been observed in clinical trials [&lt;ulink linkType="reference" linkID="319960"&gt;319960&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="367712"&gt;367712&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="368641"&gt;368641&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In a phase I study of 16 patients with either stage IIIB or IV NSCLC, a single dose of cyclophosphamide 300 mg/m2 iv was given to inhibit suppressor T-cell function. The first three patients received 20 microg of &lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; subcutaneously, the next three received 200 microg subcutaneously and the remainder were randomized to 20 microg or 200 microg on weeks 0, 2, 5 and 9. Nine patients developed self-limited injection site erythema and two developed clinically insignificant lymphopenia. In five out of 12 evaluable patients, the vaccine elicited a cytotoxic T-lymphocyte response against MUC-1-expressing cells. The median survival time of patients treated with the 20 microg dose regimen was 5.5 months, whereas it was 14.7 months for patients treated with a 200 microg dose of &lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="367786"&gt;367786&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="368999"&gt;368999&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II &lt;/subtitle&gt;In August 1999, &lt;ulink linkType="Company" linkID="14774"&gt;Biomira&lt;/ulink&gt; initiated a phase II Canadian trial of &lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; in patients with advanced NSCLC to determine if higher or more frequent dosing would enhance its effects [&lt;ulink linkType="reference" linkID="335997"&gt;335997&lt;/ulink&gt;]. The next phase of development is to administer &lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; in combination with liposomal IL-2. The purpose of the study is to determine if the effect of &lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; is enhanced by IL-2 [&lt;ulink linkType="reference" linkID="353448"&gt;353448&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2000, &lt;ulink linkType="Company" linkID="14774"&gt;Biomira&lt;/ulink&gt; initiated a phase IIb trial of &lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; in advanced NSCLC, which is expected to enroll 166 evaluable patients at approximately ten Canadian sites [&lt;ulink linkType="reference" linkID="378515"&gt;378515&lt;/ulink&gt;]. Patients with advanced NSCLC who have either stable disease or a clinical response following first-line chemotherapy will be randomized to receive either the &lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; liposome vaccine or best supportive care alone [&lt;ulink linkType="reference" linkID="385989"&gt;385989&lt;/ulink&gt;]. In October 2000, results of a phase I/II study demonstrated that in patients with NSCLC, &lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; is well tolerated and capable of generating a powerful and strong cellular immune response against MUC-1 antigen [&lt;ulink linkType="reference" linkID="385989"&gt;385989&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; is generally well tolerated, and the most frequently reported side effect in a phase I study of patients with NSCLC was fatigue [&lt;ulink linkType="reference" linkID="367712"&gt;367712&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="368641"&gt;368641&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Preclinical data suggest that MUC-1-specific T-cell responses, and for some strategies humoral immune responses, are induced with MUC-1 peptide injections. Immunization with MUC-1-based vaccines protects against metastatic disease in animal models of tumor challenge. &lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; has demonstrated safety in phase I studies and immune responses specific for MUC-1. Thus far, full data for clinical benefit is not available. The vaccine is now being tested in a randomized phase II study of patients with advanced lung cancer. Ultimately, this strategy will be competing against the many other strategies targeting MUC-1 peptide or protein that are under development. These include antibodies [&lt;ulink linkType="reference" linkID="368648"&gt;368648&lt;/ulink&gt;], dendritic cells loaded with MUC-1 [&lt;ulink linkType="reference" linkID="367712"&gt;367712&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="368641"&gt;368641&lt;/ulink&gt;], a 16-amino-acid [&lt;ulink linkType="reference" linkID="290463"&gt;290463&lt;/ulink&gt;] and a 30-amino-acid MUC-1-KLH conjugate [&lt;ulink linkType="reference" linkID="395080"&gt;395080&lt;/ulink&gt;], and other MUC-1 fusion products such as mannan-MUC-1 [&lt;ulink linkType="reference" linkID="284018"&gt;284018&lt;/ulink&gt;]. All have been shown to have some biological activity in terms of induction of immune responses, but the actual antitumor benefit is still unknown. Also competing will be approaches targeting the aberrant glycosylation pattern of mucin, such as the &lt;ulink linkType="Drug" linkID="8590"&gt;Theratope&lt;/ulink&gt; vaccine - also under development by &lt;ulink linkType="Company" linkID="14774"&gt;Biomira Inc&lt;/ulink&gt;. In addition, other MUC-1 peptide vaccines have been evaluated. Goydos and colleagues [&lt;ulink linkType="reference" linkID="323584"&gt;323584&lt;/ulink&gt;] administered a 105-amino-acid synthetic mucin MUC-1 peptide that has five repeated immunodominant sequences admixed with BCG to patients with adenocarcinoma. Although only three patients had a strong DTH response to the peptide, intense T-cell infiltration was found in more than half of skin biopsies and &amp;gt; 30% of patients had increases of 2- to 4-fold in mucin-specific CTLp. Other methods of delivering MUC-1 peptides, such as peptide-loaded poly(d,l-lactic-co-glycolic acid) (PLGA) microspheres, are in preclinical development [&lt;ulink linkType="reference" linkID="323584"&gt;323584&lt;/ulink&gt;]. At this point, no one strategy can be declared better than the others, although the &lt;ulink linkType="Drug" linkID="8590"&gt;Theratope&lt;/ulink&gt; vaccine will complete a large phase III study in 2001. &lt;ulink linkType="Drug" linkID="14169"&gt;BLP-25&lt;/ulink&gt; will perhaps have the next largest clinical dataset associated with it once the phase IIb study is completed.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-11-30T00:00:00.000Z</StatusDate><Source id="1642668" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-12T00:00:00.000Z</StatusDate><Source id="1593483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035512">EMD Serono Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-12T00:00:00.000Z</StatusDate><Source id="1593483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-12T00:00:00.000Z</StatusDate><Source id="1593483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-12T00:00:00.000Z</StatusDate><Source id="1593483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035512">EMD Serono Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-12T00:00:00.000Z</StatusDate><Source id="1593483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-07-23T00:00:00.000Z</StatusDate><Source id="1121843" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-12T00:00:00.000Z</StatusDate><Source id="1593483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18681">Ono Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-12T00:00:00.000Z</StatusDate><Source id="1593483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-07-23T00:00:00.000Z</StatusDate><Source id="1121843" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-12T00:00:00.000Z</StatusDate><Source id="1593483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-12T00:00:00.000Z</StatusDate><Source id="1593483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-07-23T00:00:00.000Z</StatusDate><Source id="1121843" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-07-23T00:00:00.000Z</StatusDate><Source id="1121843" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1055">Rectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-11-30T00:00:00.000Z</StatusDate><Source id="1642668" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-07-23T00:00:00.000Z</StatusDate><Source id="1121843" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-07-23T00:00:00.000Z</StatusDate><Source id="1121843" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-12T00:00:00.000Z</StatusDate><Source id="1593483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-10-13T00:00:00.000Z</StatusDate><Source id="508477" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-02-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14774">Cascadian Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-08-05T00:00:00.000Z</StatusDate><Source id="500140" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14774">Cascadian Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-12-23T00:00:00.000Z</StatusDate><Source id="1229742" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-23T00:00:00.000Z</StatusDate><Source id="1084904" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-23T00:00:00.000Z</StatusDate><Source id="1084904" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-23T00:00:00.000Z</StatusDate><Source id="1084904" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-23T00:00:00.000Z</StatusDate><Source id="1084904" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-23T00:00:00.000Z</StatusDate><Source id="1084904" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="IL">Israel</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-23T00:00:00.000Z</StatusDate><Source id="1084904" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-23T00:00:00.000Z</StatusDate><Source id="1084904" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-02-29T00:00:00.000Z</StatusDate><Source id="1107933" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-10-04T00:00:00.000Z</StatusDate><Source id="1227790" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18681">Ono Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-10-04T00:00:00.000Z</StatusDate><Source id="1227790" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-06-17T00:00:00.000Z</StatusDate><Source id="1108785" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-06-17T00:00:00.000Z</StatusDate><Source id="1108785" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-06-17T00:00:00.000Z</StatusDate><Source id="1108785" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-06-17T00:00:00.000Z</StatusDate><Source id="1108785" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035512">EMD Serono Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-06-17T00:00:00.000Z</StatusDate><Source id="1108785" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-06-17T00:00:00.000Z</StatusDate><Source id="1108785" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035512">EMD Serono Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-06-17T00:00:00.000Z</StatusDate><Source id="1108785" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-06-17T00:00:00.000Z</StatusDate><Source id="1108785" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1055">Rectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-01-06T00:00:00.000Z</StatusDate><Source id="1255553" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-11-30T00:00:00.000Z</StatusDate><Source id="1252817" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14774">Cascadian Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-10-22T00:00:00.000Z</StatusDate><Source id="426319" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14774">Cascadian Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-08-06T00:00:00.000Z</StatusDate><Source id="293436" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14774">Cascadian Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-12-18T00:00:00.000Z</StatusDate><Source id="193417" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-08-22T00:00:00.000Z</StatusDate><Source id="462282" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-10-01T00:00:00.000Z</StatusDate><Source id="440821" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14774">Cascadian Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-08-12T00:00:00.000Z</StatusDate><Source id="335997" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-05-04T00:00:00.000Z</StatusDate><Source id="408105" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-05-04T00:00:00.000Z</StatusDate><Source id="408105" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14774">Cascadian Therapeutics Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-03-01T00:00:00.000Z</StatusDate><Source id="399613" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14774">Cascadian Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-21T00:00:00.000Z</StatusDate><Source id="754682" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="WO">World</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-06-22T00:00:00.000Z</StatusDate><Source id="1019991" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="XE">South America</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-23T00:00:00.000Z</StatusDate><Source id="1084904" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-23T00:00:00.000Z</StatusDate><Source id="1084904" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-23T00:00:00.000Z</StatusDate><Source id="1084904" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="XH">Far East</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-23T00:00:00.000Z</StatusDate><Source id="1084904" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-23T00:00:00.000Z</StatusDate><Source id="1084904" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="IL">Israel</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-23T00:00:00.000Z</StatusDate><Source id="1084904" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-23T00:00:00.000Z</StatusDate><Source id="1084904" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="14774">Cascadian Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1262">Non-small-cell lung cancer</Indication><AwardedIndication>Treatment of Non-Small-Cell Lung Cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-09-29T00:00:00.000Z</MileStoneDate><Source id="561597" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-06235"><Name>Mucin 1</Name><SwissprotNumbers><Swissprot>P08640</Swissprot><Swissprot>P15941</Swissprot><Swissprot>Q02496</Swissprot><Swissprot>Q29435</Swissprot><Swissprot>Q60528</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=1195526" linkType="reference" linkID="1195526"&gt;1195526&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2155905" linkType="reference" linkID="2155905"&gt;2155905&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="18101">Merck KGaA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18681">Ono Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22759">Axis Genetics plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24839">Harvard Medical School</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="25554">Seattle Genetics Inc</Company><CountAsPrincipalActive>3</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>3</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="29469">Cancer Research UK</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]5CCCN5C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](Cc6c[nH]cn6)NC(=O)[C@H](C)NC(=O)[C@@H]7CCCN7C(=O)[C@@H]8CCCN8C(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)N</Smiles></StructureSmiles><Deals><Deal id="111091" title="Merck KGaA to develop and commercialize Biomira's BLP-25 and Theratope worldwide"></Deal><Deal id="117100" title="Oncothyreon to use Dana-Farber Cancer Institute's MUC-1 patents for therapeutic cancer vaccine programs   "></Deal><Deal id="119990" title="Biomira to collaboration with Axis Genetics on vaccines active MUC-1"></Deal><Deal id="125960" title="Biomira to license patent rights relating to ICRT's MUC1  peptide"></Deal><Deal id="136512" title="Ono Pharmaceutical to codevelop and comarket Merck Serono's Stimuvax in Japan for non-small cell lung cancer"></Deal></Deals><PatentFamilies><PatentFamily id="1119237" number="WO-2010078045" title="Method of making small liposomes"></PatentFamily><PatentFamily id="1683074" number="WO-00034468" title="MUC-1 antagonists and methods of treating immune disorders"></PatentFamily><PatentFamily id="1831095" number="WO-09911654" title="Randomly generated glycopeptide combinatorial libraries."></PatentFamily><PatentFamily id="2094212" number="WO-09817300" title="Mucin-Mediated Immunomodulation"></PatentFamily><PatentFamily id="2125719" number="WO-09204048" title="Inhibition Of Metastasis Potential And Invasiveness By Oligosaccharides Or Oligosaccharide Antigens Or Antibodies"></PatentFamily><PatentFamily id="2830363" number="WO-2014183823" title="Method of treating lung cancer by vaccination with muc-1 lipopeptide"></PatentFamily><PatentFamily id="2925160" number="WO-2015058831" title="Elevated biomarker expression in lung cancer patients responding to treatment with MUC-1 lipopeptide vaccines"></PatentFamily><PatentFamily id="351624" number="WO-08805054" title="Probe"></PatentFamily><PatentFamily id="724814" number="WO-09109867" title="Mucin nucleotides."></PatentFamily><PatentFamily id="922018" number="WO-2007015171" title="Method of treating patients with a mucinous glycoprotein (muc-1) vaccine"></PatentFamily><PatentFamily id="977195" number="WO-09005142" title="Polypeptides"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biomembrane Institute" id="14767"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck KGaA" id="18101"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ono Pharmaceutical Co Ltd" id="18681"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Seattle Genetics Inc" id="25554"></CompanyLink><CountAsOwner>9</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cancer Research UK" id="29469"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>